examined the prognostic value of other parameters, such as DNA ploidy, Ki-67 (a monoclonal antibody, which reacts with a nuclear antigen expressed in all phases of the cell cycle except G 0 ), and apoptosis, in heterogeneous groups of STS patients. Overall, aneuploidy, a high amount of Ki-67, and low frequencies of apoptotic cells seem to be related to a worse clinical outcome in patients with different types of STS. The signi cance of the above-mentioned parameters may differ among various histological types of STS, which may be the reason for inconsistent results between different studies. 6, 7 Studies focusing exclusively on LMS, express the signi cance of the site of the tumor on its behaviour, i.e., the prognosis of patients with (sub)cutaneous LMS is better than that of patients with deep-seated LMS, despite their similar histological and tumor biological features. 1, [8] [9] [10] [11] Jensen et al. recommended that super cial LMS be separated further into lesions with predominant cutaneous growth and tumors that involve the subcutis, since cutaneous LMS generally have a better prognosis, and only tumors involving the subcutis have the tendency to metastasize. In the diagnosis of smooth muscle tumors, the distinction between malignant and benign may be dif cult. 1 Factors which discriminate most in the clinical differential diagnosis are tumor size and location, benign tumors usually being small and located super cially.
14 To date, no study has compared (sub)cutaneous LMS with (sub)cutaneous LM.
The aim of this study is to nd possible differences between LMS of deep soft tissue (excluding gastrointestinal stromal tumors and urogenital tumors), subcutaneous and cutaneous tissue, and to determine whether proliferation markers (mitotic and Ki-67 indices), size, grade, DNA ploidy and the amount of apoptosis correlate with the differences in their biological and clinical behaviour. We also analysed differences between LMS and LM of the cutis and subcutis, in order to nd new diagnostic criteria.
Patients
We collected all available material of all patients diagnosed between 1980 and 1998 with a LMS or a super cial LM in the northern region of The Netherlands. Material of 16 patients with super cial LM(S) was donated by the Department of Dermatopathology, Fachklinik Hornheide in Germany. The diagnosis was based on the criteria of Enzinger and Weiss, 1 using light microscopic examination of hematoxylin-eosin (HE)-stained paraf n sections, and, when necessary, the diagnosis was con rmed immunohistochemically using antibodies to actin and desmin. A total of 62 patients were included in the present study.
Material was obtained from 27 patients with a primary LMS of deep soft tissue ( Table 1 ). The median age was 60 (range 20-83) years. Thirteen patients had extremity tumors, whereas three patients had a retroperitoneal LMS.
Fourteen patients with a super cial LMS (Table 1 ) were included in this study. The median age was 62 (range 23-85) years. Three patients had a tumor con ned to the cutis, whereas seven patients had a super cial LMS involving both the cutis and the subcutis. The remaining four patients had a tumor con ned to the subcutis.
Twenty-one patients with a super cial LM (Table  1) were analysed. Except for one, all tumors were con ned to the cutis, so no distinction was made between cutaneous or subcutaneous tumors. The median age was 56 (range 7-83) years. A tumor was considered a LM, when no mitoses were found.
The patient records were used to collect the clinical data. Overall survival (OS) and survival status (NED, no evidence of disease; AWD, alive with disease; DOD, died of disease; DOC, died of other causes; LOF, lost to follow-up) were recorded for the patients with a deep and super cial LMS. Recurrence and metastatic disease were recorded as well (Table 1) .
Methods

Grading
The LMS were graded according to the system described by Coindre et al., 15 in which points are assigned to differentiation level (1, closely resembling normal tissue; 2, certain histogenetic classi cation; 3, undifferentiated), mitotic index per 2 mm 2 (1, 0-9; 2, 10-19; 3, 20 or more) and necrosis (0, none; 1, less than 50%; 2, more than 50%). Tumors with a total score of 2 or 3 were graded as grade I, those with a total score of 4 or 5 as grade II and those with a total score of 6-8 as grade III.
DNA ploidy
DNA ow cytometry was performed on single cell suspensions obtained from formalin-xed paraf nembedded tissue or fresh tissue, as previously described by Plaat et al. 6 The DNA pro le was considered (near)diploid when a single stem line was present in the diploid range; all others were considered aneuploid.
Proliferation and apoptosis
For proliferation, the monoclonal antibody MIB 1, which recognizes the Ki-67 antigen, was used (Immunotech S.A., Marseille, France). Immunohistochemistry was performed on paraf n sections (4 µm) according to a method modi ed from Shi et al. 16, 17 Apoptosis was studied in 4-µm sections of formaldehyde-xed and paraf n-embedded tissue using the TUNEL (terminal deoxynucleotidyl transferase (TdT) mediated dUTP nick end labeling) method, as previously described by Plaat et al. 18 
Quanti cation of Ki-67 and apoptosis
For measuring the Ki-67 labeling index and the apoptotic labeling index we used ocular micrometry on a Leitz microscope by using an eyepiece grid at 400 magni cation. Fifteen elds were randomly selected throughout histologically viable areas. The positive and negative nuclei were counted. Endothelial cells, in ammatory cells and necrosis were excluded. The number of positive nuclei was then divided by the total number of nuclei in each of the fteen randomly selected elds to calculate an index per eld. The Ki-67 and the apoptotic indices were de ned as the mean of the indices of the 15 randomly selected elds.
Statistical analysis
To compare OS and survival status in relation to grade, size, DNA ploidy, and Ki-67 and apoptotic indices, survival curves were constructed by the Kaplan-Meier method. Survival curves in the different groups were compared by the log-rank test. A m 2 -test or m 2 -test for trend was used to estimate the differences in tumor grade and DNA ploidy. A MannWhitney U-test was used to analyse the differences between proliferation markers (mitoses, Ki-67), apoptosis and size in the different groups. A p value of <0.05 was considered statistically signi cant.
Results
The results of the different groups are shown in Table  2 . Due to technical failures and in some cases to insuf cient material, not all tumors could be analysed for Ki-67 and apoptotic indices, grading, or DNA ploidy. By analyzing the total group of 41 patients with a LMS, no signi cant correlations were found between OS and mitotic, Ki-67 indices, apoptotic indices, grade, or DNA ploidy (Table 2) .
Deep versus super cial LMS
Patients with a super cial LMS had a signi cantly better OS compared to patients with a deep LMS (Fig.1) . More than half of all patients with a deep LMS died of the tumor (52%). This is in contrast with super cial LMS, where none of the patients died of the tumor. No differences were found between deep and super cial LMS for mitotic, Ki-67 or apoptotic indices, nor for grade and DNA ploidy ( Table  2 ). Super cial LMS had a signi cantly (p = 0.001) smaller size than deep LMS; 2.5 vs. 9.5 cm (Fig. 2) .
Cutaneous versus subcutaneous LMS
Of the 14 super cial LMS, three tumors were limited to the cutis, four to the subcutis, and seven tumors involved both the cutis and the subcutis ( Table 1) .
None of the three entirely cutaneous LMS metastasized, whereas three of the four subcutaneous tumors metastasized. None of the seven cutaneous/subcutaneous tumors metastasized, although two of them showed a local recurrence (p > 0.5). No statistical differences were found between mitotic, Ki-67 and apoptotic indices, grade, and DNA ploidy between the three groups ( Table 2) .
Super cial LM versus super cial LMS
The super cial LMS had a mean Ki-67 index of 8.4% and a mean apoptotic index of 0.33%. In the LM this was 1.0 and 0.01%, respectively (p < 0.005) (Figs. 3 and 4) . Two super cial LMS were diploid, two were aneuploid. All of the LM were diploid (p = 0.19).
Discussion
The signi cance of various prognostic factors, such as DNA ploidy, Ki-67 and apoptotic indices, may differ among various types of STS. [2] [3] [4] [5] [6] [7] Most studies include only a few smooth muscle tumors, or compare different types, so that interpretation of the results is not always easy. LMS is a rare tumor, and its behaviour seems to depend on the site of the tumor.
8-11 Therefore we studied LMS of deep and super cial tissue as one group to identify site-independent prognostic markers, which could explain the differences in biological behaviour. LMS and LM of the skin were also compared to nd consistent differences that could aid in the differential diagnosis of malignant and benign super cial smooth muscle tumors.
Forty-one patients with a deep or super cial LMS were analysed in order to nd factors that could predict clinical outcome. Although studies examining
Smooth muscle tumors large groups of heterogeneous STS showed a relation between a high Ki-67 index and malignancy, 2 low apoptotic index and low grade, 3 and aneuploidy and bad prognosis, 4,5 we did not con rm any of these ndings. This is similar to the ndings of Gustafson et al., 19 who did not nd any relationship between DNA ploidy and prognosis either. Although in our study patients with a high-grade LMS did have a worse prognosis, this was not statistically signi cant, which may be due to the limited number of LMS studied.
The prognosis of the patients with a super cial LMS was signi cantly better than that of patients with a deep LMS, which is in agreement with other studies. 1, 8 We found no difference in proliferation markers (Ki-67 and mitotic indices), DNA ploidy and the amount of apoptosis. In a previous study, deep seated LMS with a high amount of Ki-67 tended to have a worse prognosis, but this was also not signi cant. 8 Although there seems to be a difference in grade between the two groups, i.e. deep LMS showing more high-grade tumors than super cial LMS (27 against 8%), this was not statistically significant. The different biological behaviour of these two types of tumors, seems to be only associated with their different locations. This is similar to a previous study, where LMS in super cial and deep soft tissues were almost the same with regard to cell proliferation and alteration of the p53 gene. 8 However, we found a signi cantly different size between the two groups (deep LMS being larger than super cial LMS), which also could explain the different outcome. It seems plausible that super cial LMS are earlier discovered, so that their growth is limited. The conclusion is that the different outcome seems to be related only to the location and size, the latter probably being the most important.
Within the group of super cial LMS, site seems also to be of importance in cutaneous and subcutaneous tumors, as they have a different prognosis. Tumors con ned to the cutis seem to have a better clinical outcome. 1, 10, 11 Identifying patients with a greater risk of metastasis is important to determine the prognosis or therapy. In agreement with other studies, [11] [12] [13] only tumors con ned to the subcutis metastasized. We found that patients with a LMS con ned to the cutis, did not show metastasis or recurrences. Proliferation and apoptosis did not predict metastatic potential in super cial LMS, nor did any of the other parameters. Although in one study only patients with diploid super cial LMS had metastases, 20 we did not nd any relation between malignancy and DNA ploidy. Analyses of larger groups maybe necessary to examine the relevance of DNA ploidy. The impaired prognosis might be related to location alone, contrary to deep and supercial LMS where size may also be of importance. Patients with a tumor involving both the cutis and the subcutis did not metastasize, but some of the patients had a local recurrence. It seems that this last group is of dermal origin, with invasion of the subcutis. Only tumors arising in the subcutis tend to metastasize; whether these two groups are different must be further examined. One explanation might be the difference in origin; the cutaneous LMS are usually arising from pilar arecti, and subcutaneous LMS are mostly from vascular origin. 21 As mentioned above, differentiation between LM and LMS may be dif cult. In rare cases, diagnosis can be hard, imposing dif culties upon the choice of the right therapy and expected clinical behaviour. 1 In agreement with one previous study, 22 comparing different types of LM and LMS, the amount of apoptosis and proliferation were signi cantly higher in the super cial LMS compared to the LM. This is in contrast with another study, series of tumor samples. It may be possible that these results also apply to other types of malignant and benign smooth muscle tumors, and might aid in the diagnosis of dif cult cases.
In summary, our study shows that the clinical behaviour of different types of LMS seems to be related to the site of the tumor alone. The smaller tumor size in patients with a super cial LMS, compared to deep, is probably due to the early discovery of this kind of LMS, and may also be the main reason for the better clinical outcome of these patients. The reason why subcutaneous LMS have a worse prognosis than entirely cutaneous LMS is not yet clear, but might be related to the tumor origin. Further examination is necessary to nd out of these types of LMS have a different oncogenesis, which may account for their different behaviour. Dif culties in the diagnosis between super cial LMS and LM, can be facilitated by determination of the amount of apoptosis and proliferation.
